Page 12 - Cipla

Sensex, Nifty end flat after volatile session; metal, energy stocks shine

CLOSING BELL: M&M, Tech M, Dr Reddy's Labs, Reliance Industries, HCL Tech, and Tata Steel were the top gainers on the 30-pack index

Stocks to watch: Bajaj Auto, TVS Motor, Tata Steel, Cipla, JSW Steel, FRL

Stocks to watch today: Bajaj Auto approved buyback of shares worth up to Rs 2,500 crore; Moody's upgraded Tata Steel's outlook to 'positive' from 'stable'

Cipla to invest Rs 26 cr in digital tech co GoApptiv to raise stake to 22%

Pharma company Cipla has agreed to acquire an additional stake for nearly Rs 26 crore in digital tech company GoApptiv Private to raise its shareholding to 22.02 per cent, the company said on Monday. The investment will be made in equity shares and Compulsorily Convertible Preference Shares and is likely to be completed within 30 days or such other date mutually agreed between the parties, Cipla said in a regulatory filing. Cipla's earlier investment in GoApptiv in June 2020 has yielded growth and expanded Cipla's channel reach across lower tier towns in India. "This investment will further strengthen our partnership with GoApptiv enabling wider patient reach with affordable and quality drugs and end-to-end brand marketing and channel engagement across tier 2-6 towns in India. 'Caring for Life' is at the heart of what we do and will guide us towards making such strategic investments to help make a difference in the lives of our patients," Umang Vohra, MD and Global CEO, Cipla Limite

Cipla to acquire 21% stake in diagnostic company Achira Labs for Rs 25 cr

The company has signed definitive agreements with Achira Labs for the purpose, Cipla said in a regulatory filing

Sensex ends 152 pts lower ahead of US Fed decision; Nifty dips below 15,700

CLOSING BELL: NTPC, Infosys, HUL, Wipro, and RIL slipped over 1 per cent each

Caring for patients runs in our DNA, say Cipla's Samina Hamied, Umang Vohra

'Cipla has so many capabilities that for anything we need to do, we say we can do it'

Rejuvenating Cipla: After global expansion, acquisitions on cards

Having consolidated its presence across geographies, the pharma major is looking at acquisitions

Stocks to Watch: CoForge, MRPL, Petronet, JSW Ispat, PNB, Birla Corp, PSBs

Stocks to Watch Today: Aditya Birla Capital, Apollo Tyres, GSPL, HCC, L&T, RBL Bank, Siemens and Tata Motors ahead of Q4 earnings; Prudent Corporate Advisory Services IPO to close on Thursday.

Cipla looks to invest more in mRNA tech; holds discussions with firms

Speaking to Business Standard, Samina Hamied, executive vice chairperson, Cipla, says one must invest in research and development (R&D) to feed the commercial growth engines

Cipla will use Covid-19 bulk drugs inventory when demand rises

The Covid-19 portfolio contributed 5-6 per cent of Cipla's turnover during peak Covid waves, the firm said

Sensex ends 277pts lower, Nifty 73pts; L&T, Bajaj twins slip; banks rebound

In the primary market, Venus Pipes & Tubes IPO was subscribed 2 times on Day 1 of the offer period; Delhivery IPO was off to a slow start.

Stocks to Watch: SBI, Cipla, Voda Idea, Gujarat Gas, Zensar, MGL, Welspun

Stocks to Watch Today: The primary market too is likely to be abuzz with activity with three IPOs namely - Delhivery, Prudent Corporate Advisory Services IPO and Venus Pipes IPO open for subscription.

Cipla Q4 PAT dips 12% to Rs 362 cr owing to Covid inventory impact

For the full fiscal, Cipla has posted a 4.7% jump in net profit to Rs 2,517 crore, revenue and Ebitda rose 13.6% and 6.4% respectively

Cipla partners with Genes2Me to launch Coronavirus RT PCR test kit

The kit is validated by the Indian Council of Medical Research (ICMR) and much more advanced than other RT PCR tests, the drug firm said

Winners of BS Awards 2021 capture India Inc's growth story

Business Standard Annual Awards for Corporate Excellence 2021 were announced this week. The winners were picked by an eight-member jury after extensive deliberations and capture India's growth story

Cipla, Ipca Lab, Zydus Life to benefit most from drug price rise: Analysts

The recent price hike, analysts said, brings some respite for the industry facing multiple headwinds such as steep raw inflation, price erosion in the US market and higher freight costs.

Select pharma shares gain on tie-up for Pfizer Covid-19 oral treatment drug

Among individual stocks, Aurobindo Pharma was the top gainer, which rallied 8 per cent to Rs 688.90 on the BSE in intra-day trade.

Cipla hits fresh all-time high in a volatile market; rallies 12% in 1 week

Going forward, significant momentum in Cipla will likely continue due to US gains on the back of peptide portfolio unlocking and possible approvals and launches of gRevlimid, gAdvair and gAbraxane

Pharma stocks surge on positive cues from Nifty healthcare, Cipla up 6%

Outlook for Indian drug exporters turned positive on prospects of firm exports amid the ongoing geo-political scenario, said analysts

Cipla gains 3%, hits record high; trades higher for 5th straight day

Analysts at ICICI Securities have maintained a 'buy' rating on the stock with target price of Rs 1,100 on the stock